Indegene Limited — Investor Meet, 02-05-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Indegene reported Q4 revenue at INR755.6 Cr, up 12.3% YoY and 4.9% QoQ, led by commercial and medical segments. EBITDA rose 1.7% QoQ to INR152.6 Cr (20.2% margin), while PAT increased 7.2% QoQ to INR117.6 Cr, boosted by tax benefits. FY25 revenue stands at INR2839.3 Cr (+9.6%), with PAT growing 20.8% to INR406.7 Cr. Client growth slowed due to two large accounts but new $1M+ clients rose to 41. Acquisitions enhanced medical writing and creative services. Management is cautiously optimistic, highlighting GenAI platform Cortex traction, stable margins, and a strong cash position of INR1664 Cr. Dividend proposed at INR48 Cr.